Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Checkpoint Therapeutics stock
Learn how to easily invest in Checkpoint Therapeutics stock.
Checkpoint Therapeutics Inc is a biotechnology business based in the US. Checkpoint Therapeutics shares (CKPT) are listed on the NASDAQ and all prices are listed in US Dollars. Checkpoint Therapeutics employs 10 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Checkpoint Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CKPT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Checkpoint Therapeutics stock price (NASDAQ: CKPT)Use our graph to track the performance of CKPT stocks over time.
Checkpoint Therapeutics shares at a glance
|Latest market close||$2.45|
|52-week range||$2.22 - $5.38|
|50-day moving average||$3.21|
|200-day moving average||$3.01|
|Wall St. target price||$15.80|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.52|
Buy Checkpoint Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Checkpoint Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Checkpoint Therapeutics price performance over time
|1 week (2022-01-09)||N/A|
|1 month (2021-12-17)||-16.67%|
|3 months (2021-10-18)||-22.47%|
|6 months (2021-07-20)||-12.19%|
|1 year (2021-01-20)||-33.60%|
|2 years (2020-01-17)||35.36%|
|3 years (2019-01-18)||3.6|
|5 years (2017-01-20)||11|
Checkpoint Therapeutics financials
|Gross profit TTM||$-15,283,000|
|Return on assets TTM||-44.87%|
|Return on equity TTM||-88.22%|
|Market capitalisation||$218.6 million|
TTM: trailing 12 months
Checkpoint Therapeutics share dividends
We're not expecting Checkpoint Therapeutics to pay a dividend over the next 12 months.
Checkpoint Therapeutics share price volatility
Over the last 12 months, Checkpoint Therapeutics's shares have ranged in value from as little as $2.22 up to $5.376. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Checkpoint Therapeutics's is 1.6031. This would suggest that Checkpoint Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Checkpoint Therapeutics overview
Checkpoint Therapeutics, Inc. , a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7. 1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing CK-101, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc.
Checkpoint Therapeutics in the news
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Frequently asked questionsWhat percentage of Checkpoint Therapeutics is owned by insiders or institutions?
Currently 15.664% of Checkpoint Therapeutics shares are held by insiders and 14.02% by institutions. How many people work for Checkpoint Therapeutics?
Latest data suggests 10 work at Checkpoint Therapeutics. When does the fiscal year end for Checkpoint Therapeutics?
Checkpoint Therapeutics's fiscal year ends in December. Where is Checkpoint Therapeutics based?
Checkpoint Therapeutics's address is: 2 Gansevoort Street, New York, NY, United States, 10014 What is Checkpoint Therapeutics's ISIN number?
Checkpoint Therapeutics's international securities identification number is: US1628281073 What is Checkpoint Therapeutics's CUSIP number?
Checkpoint Therapeutics's Committee on Uniform Securities Identification Procedures number is: 162828107
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Ask an Expert